An Open-Label One-way Interaction Clinical Trial to Evaluate the Pharmacokinetic Interactions Between GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Subjects
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Period 1: Maximum Observed Concentration (Cmax) of TAF
研究概览
简要总结
Human immunodeficiency virus (HIV) infection frequently involves combination drug therapy for its treatment; hence, it is important to understand their interactions and resulting changes in exposure which are associated with medications. This is a Phase-1, open-label, fixed-sequence 2-period, one-way drug interaction study to assess the pharmacokinetic (PK), safety, and tolerability of GSK3640254 and Tenofovir alafenamide/emtricitabine (TAF/FTC) when administered alone and in combination in healthy subjects. The study will consist of a screening period of 28 days before the first dose of study intervention followed by 2 sequential treatment periods. Subjects will be administered TAF/FTC 25/200 milligram (mg) once daily (QD) on Days 1 to 14 of Period 1 followed by co-administration of TAF/FTC 25/200 mg QD with GSK3640254 200 mg QD on Days 1 to 7 of Period 2.
研究设计
- 研究类型
- Interventional
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject must be 18 to 55 years of age inclusive, at the time of signing the informed consent.
- •Subjects who are healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring (history and ECG).
- •Body weight >=50.0 kilograms (kg) (110 pound [lbs]) for men and >=45.0 kilograms [kg] (99 lbs) for women and body mass index (BMI) within the range 18.5 to 31.0 kilograms per meter square (kg/m^2) (inclusive).
- •Male or female; A female subject is eligible to participate if she is not pregnant, not breastfeeding and not a woman of childbearing potential (WOCBP).
- •Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and protocol.
排除标准
- •Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- •A pre-existing condition interfering with normal gastrointestinal (GI) anatomy or motility (e.g.,gastroesophageal reflux disease, gastric ulcers, gastritis), hepatic and/or renal function, that could interfere with the absorption, metabolism and/or excretion of the study drugs or render the subject unable to take oral study intervention.
- •Any history of significant underlying psychiatric disorder including, but not limited to, schizophrenia, bipolar disorder with or without psychotic symptoms, other psychotic disorders, or schizotypal (personality) disorder.
- •Any history of major depressive disorder with or without suicidal features or anxiety disorders, that required medical intervention (pharmacologic or not) such as hospitalization or other inpatient treatment and/or chronic (>6 months) outpatient treatment. Subjects with other conditions such as adjustment disorder or dysthymia that have required shorter term medical therapy (<6 months) without inpatient treatment and are currently well-controlled clinically or resolved may be considered for entry after discussion and agreement with the ViiV Medical Monitor.
- •Any pre-existing physical or other psychiatric condition (including alcohol or drug abuse), which, in the opinion of the investigator (with or without psychiatric evaluation), could interfere with the subject's ability to comply with the dosing schedule and protocol evaluations or which might compromise the safety of the subject.
- •Medical history of cardiac arrhythmias or cardiac disease or a family or personal history of long QT syndrome.
- •History of any kidney disease or current or chronic history of impaired renal function as indicated by an estimated creatinine clearance <80 milliliters per minute (mL/min). Creatinine clearance (CrCL) is estimated by either of the following methods: (a) The Modification of Diet in Renal Disease (MDRD) equation: estimated glomerular filtration rate (eGFR) (milliliter [mL]/minute [min]/1.73 meter square [m^2]) = 175 x (SCr)^-1.154 x (Age)^-0.203 x 0.742 [if female] x 1.212 [if African American] glomerular filtration rate (GFR) is expressed in mL/min/1.73 m^2, SCr is serum creatinine expressed in milligrams per deciliter (mg/dL), and age is expressed in years. (b)The Cockcroft-Gault equation: CrCL(mL/min) ={((l40-age) x weight)/(72xSCr)}x 0.85 (if female) CrCL is expressed in mL/min, age is expressed in years, weight is expressed in kg, and SCr is serum creatinine expressed in mg/dL.
- •Presence of Hepatitis B surface antigen (HBsAg) at Screening or within 3 months prior to starting study intervention.
- •Positive Hepatitis C antibody test result at Screening or within 3 months prior to starting study intervention AND positive on reflex to Hepatitis C ribonucleic acid (RNA).
- •Positive HIV-1 and -2 antigen/antibody immunoassay at Screening.
- •ALT >1.5 × upper limit of normal (ULN). A single repeat of ALT is allowed within a single screening period to determine eligibility.
- •Bilirubin >1.5 × ULN (isolated bilirubin >1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- •Any acute laboratory abnormality at Screening which, in the opinion of the investigator, should preclude participation in the study of an investigational compound.
- •Any Grade 2 to 4 laboratory abnormality at Screening, with the exception of creatine phosphokinase (CPK) and lipid abnormalities (e.g., total cholesterol, triglycerides, etc), and ALT (described above), will exclude a subject from the study unless the investigator can provide a compelling explanation for the laboratory result(s) and has the assent of the sponsor. A single repeat of any laboratory abnormality is allowed within a single screening period to determine eligibility.
- •A positive test result for drugs of abuse (including marijuana), alcohol, or cotinine (indicating active current smoking) at Screening or before the first dose of study intervention.
- •Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication and for the duration of the study.
- •Treatment with any vaccine within 30 days prior to receiving study intervention.
- •Unwillingness to abstain from excessive consumption of any food or drink containing grapefruit and grapefruit juice, Seville oranges, blood oranges, or pomelos or their fruit juices within 7 days prior to the first dose of study intervention(s) until the end of the study.
- •Participation in another concurrent clinical study or prior clinical study (with the exception of imaging trials) prior to the first dosing day in the current study: 30 days, 5 half-lives, or twice the duration of the biological effect of the study intervention (whichever is longer).
- •Where participation in the study would result in donation of blood or blood products in excess of 500 mL within 56 days.
- •Any positive (abnormal) response confirmed by the investigator on a screening clinician- or qualified designee-administered Columbia-Suicide Severity Rating Scale (C-SSRS).
- •Any significant arrhythmia or ECG finding (e.g., prior myocardial infarction, sinoatrial pauses, bundle branch block, or conduction abnormality) which, in the opinion of the investigator or VH/GSK Medical Monitor, will interfere with the safety for the individual subject.
- •Exclusion criteria for screening ECG (a single repeat is allowed for eligibility determination): Heart rate for male: <45 or >100 beats per minute (bpm) and for females: <50 or >100 bpm; PR interval: <120 or >200 milliseconds (msec); QRS duration: <70 or >110 msec and QTcF interval for male: >450 msec and for female: >470 msec. A heart rate from 100 to 110 bpm can be rechecked by ECG or vital signs within 30 minutes to verify eligibility.
- •History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of >14 units. One unit is equivalent to 8 grams of alcohol: a half-pint (equivalent to 240 mL) of beer, 1 glass (125 mL) of wine, or 1 (25 mL) measure of spirits.
- •Regular use of tobacco- or nicotine-containing products within 3 months prior to Screening.
- •History of sensitivity to any of the study medications or components thereof or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.
研究组 & 干预措施
TAF/FTC followed by TAF/FTC + GSK3640254
Subjects will receive TAF/FTC 25/200 mg QD on Days 1 through 14 in Treatment Period 1. Subjects will be co-administered TAF/FTC 25/200 mg QD with GSK3640254 200 mg QD on Days 1 through 7 in Treatment Period 2.
干预措施: Tenofovir alafenamide/emtricitabine (Drug)
TAF/FTC followed by TAF/FTC + GSK3640254
Subjects will receive TAF/FTC 25/200 mg QD on Days 1 through 14 in Treatment Period 1. Subjects will be co-administered TAF/FTC 25/200 mg QD with GSK3640254 200 mg QD on Days 1 through 7 in Treatment Period 2.
干预措施: GSK3640254 (Drug)
结局指标
主要结局
Period 1: Maximum Observed Concentration (Cmax) of TAF
时间窗: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis.
Period 2:Cmax of FTC
时间窗: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis.
Period 1: AUC (0-tau) of Tenofovir (TFV)
时间窗: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis.
Period 1: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing Interval at Steady State (AUC [0-tau]) of TAF
时间窗: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). Pharmacokinetic (PK) parameters were calculated by standard non-compartmental analysis. PK Parameter Population included all participants who underwent plasma PK sampling and had evaluable PK parameters estimated.
Period 2: AUC (0-tau) of FTC
时间窗: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis.
Period 2: AUC (0-tau) of TAF
时间窗: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis.
Period 2: Cmax of TAF
时间窗: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis.
Period 1: AUC (0-tau) of FTC
时间窗: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis.
Period 1:Cmax of FTC
时间窗: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis.
Period 1: Plasma Concentration at the End of the Dosing Interval (Ctau) of FTC
时间窗: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
Blood samples were collected at indicated time-points for analysis of Ctau. PK parameters were calculated by standard non-compartmental analysis.
Period 2: Ctau of FTC
时间窗: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Blood samples were collected at indicated time-points for analysis of Ctau. PK parameters were calculated by standard non-compartmental analysis.
Period 1: Cmax of TFV
时间窗: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis.
Period 2: Cmax of TFV
时间窗: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis.
Period 1: Ctau of TFV
时间窗: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
Blood samples were collected at indicated time-points for analysis of Ctau. PK parameters were calculated by standard non-compartmental analysis.
Period 2: Ctau of TFV
时间窗: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Blood samples were collected at indicated time-points for analysis of Ctau. PK parameters were calculated by standard non-compartmental analysis.
Period 2: AUC (0-tau) of TFV
时间窗: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis.
次要结局
- Period 1: Absolute Values of the Hematology Parameter: Hematocrit(Baseline and at Days 7, 14)
- Period 2: Absolute Values of the Hematology Parameter: Hematocrit(Baseline and at Days 3, 7, 9)
- Period 1: Change From Baseline in Hematology Parameter of Hemoglobin(Baseline and at Days 7, 14)
- Period 2: Change From Baseline in Hematology Parameter of Hemoglobin(Baseline and at Days 3, 7, 9)
- Period 1: Absolute Values of the Hematology Parameter: Hemoglobin(Baseline and at Days 7, 14)
- Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAE)(Up to Day 24)
- Period 1: Change From Baseline in Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils(Baseline and at Days 7, and 14)
- Period 2: Change From Baseline in Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils(Baseline and at Days 3, 7, 9)
- Period 1: Absolute Values of the Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils(Baseline and at Days 7, and 14)
- Period 2: Absolute Values of the Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils(Baseline and at Days 3, 7, 9)
- Period 1: Change From Baseline in Hematology Parameter of Hematocrit(Baseline and at Days 7, 14)
- Period 2: Change From Baseline in Hematology Parameter of Hematocrit(Baseline and at Days 3, 7, 9)
- Period 2: Absolute Values of the Hematology Parameter: Hemoglobin(Baseline and at Days 3, 7, 9)
- Period 1: Change From Baseline in Hematology Parameter of Mean Corpuscle Hemoglobin (MCH)(Baseline and at Days 7, 14)
- Period 2: Change From Baseline in Hematology Parameter of MCH(Baseline and at Days 3, 7, 9)
- Period 1: Absolute Values of the Hematology Parameter: MCH(Baseline and at Days 7, 14)
- Period 2: Absolute Values of the Hematology Parameter: MCH(Baseline and at Days 3, 7, 9)
- Period 1: Change From Baseline in Hematology Parameter of Mean Corpuscle Volume (MCV)(Baseline and at Days 7, 14)
- Period 2: Change From Baseline in Hematology Parameter of MCV(Baseline and at Days 3, 7, 9)
- Period 1: Absolute Values of the Hematology Parameter: MCV(Baseline and at Days 7, 14)
- Period 2: Absolute Values of the Hematology Parameter: MCV(Baseline and at Days 3, 7, 9)
- Period 1: Change From Baseline in Hematology Parameter of Erythrocytes(Baseline and at Days 7, 14)
- Period 2: Change From Baseline in Hematology Parameter of Erythrocytes(Baseline and at Days 3, 7, 9)
- Period 1: Absolute Values of the Hematology Parameter: Erythrocytes(Baseline and at Days 7, 14)
- Period 2: Absolute Values of the Hematology Parameter: Erythrocytes(Baseline and at Days 3, 7, 9)
- Period 1: Change From Baseline in Clinical Chemistry Parameter of Glucose, Anion Gap, Cholesterol, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), Carbon Dioxide (CO2), Chloride and Phosphorus(Baseline and at Days 7, 14)
- Period 2: Change From Baseline in Clinical Chemistry Parameter of Glucose, Anion Gap, Cholesterol, Calcium, Potassium, Sodium, BUN, CO2, Chloride and Phosphorus(Baseline and at Days 3, 7, 9)
- Period 1: Absolute Values of Clinical Chemistry Parameter of Glucose, Anion Gap, Cholesterol, Calcium, Potassium, Sodium, BUN, CO2, Chloride and Phosphorus(Baseline and at Days 7, 14)
- Period 2: Absolute Values of Clinical Chemistry Parameter of Glucose, Anion Gap, Cholesterol, Calcium, Potassium, Sodium, BUN, CO2, Chloride and Phosphorus(Baseline and at Days 3, 7, 9)
- Period 1: Change From Baseline in Clinical Chemistry Parameter of Alkaline Phosphatase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Lactate Dehydrogenase (LDH), Gamma-glutamyl Transferase (GGT), and Creatine Phosphokinase (CK)(Baseline and at Days 7, 14)
- Period 2: Change From Baseline in Clinical Chemistry Parameter of Alkaline Phosphatase, ALT, AST, LDH, GGT, and CK(Baseline and at Days 3, 7, 9)
- Period 1: Absolute Values of Clinical Chemistry Parameter of Alkaline Phosphatase, ALT, AST, LDH, GGT, and CK(Baseline and at Days 7, 14)
- Period 2: Absolute Values of Clinical Chemistry Parameter of Alkaline Phosphatase, ALT, AST, LDH, GGT, and CK(Baseline and at Days 3, 7, 9)
- Period 1: Change From Baseline in Clinical Chemistry Parameter of Total Protein, Albumin and Globulin(Baseline and at Days 7, 14)
- Period 2: Change From Baseline in Clinical Chemistry Parameter of Total Protein, Albumin and Globulin(Baseline and at Days 3, 7, 9)
- Period 1: Absolute Values of Clinical Chemistry Parameter of Total Protein, Albumin and Globulin(Baseline and at Days 7, 14)
- Period 2: Absolute Values of Clinical Chemistry Parameter of Total Protein, Albumin and Globulin(Baseline and at Days 3, 7, 9)
- Period 1: Change From Baseline in Clinical Chemistry Parameter of Lipase and Amylase(Baseline and at Days 7, 14)
- Period 2: Change From Baseline in Clinical Chemistry Parameter of Lipase and Amylase(Baseline and at Days 3, 7, 9)
- Period 1: Absolute Values of Chemistry Parameters of Lipase and Amylase(Baseline and at Days 7, 14)
- Period 2: Absolute Values of Chemistry Parameters of Lipase and Amylase(Baseline and at Days 3, 7, 9)
- Period 1: Change From Baseline in Clinical Chemistry Parameter of Total Bilirubin, Direct Bilirubin, and Creatinine(Baseline and at Days 7, 14)
- Period 2: Change From Baseline in Clinical Chemistry Parameter of Total Bilirubin, Direct Bilirubin, and Creatinine(Baseline and at Days 3, 7, 9)
- Period 1: Absolute Values of Clinical Chemistry Parameter of Total Bilirubin, Direct Bilirubin, and Creatinine(Baseline and at Days 7, 14)
- Period 2: Absolute Values of Clinical Chemistry Parameter of Total Bilirubin, Direct Bilirubin, and Creatinine(Baseline and at Days 3, 7, 9)
- Period 1: Change From Baseline in Specific Gravity of Urine(Baseline and at Days 7, 14)
- Period 2: Change From Baseline in Specific Gravity of Urine(Baseline and at Days 3, 7, 9)
- Period 1: Absolute Values of Specific Gravity of Urine(Baseline and at Days 7, 14)
- Period 2: Absolute Values of Specific Gravity of Urine(Baseline and at Days 3, 7, 9)
- Period 1: Change From Baseline in Potential of Hydrogen (pH) of Urine(Baseline and at Days 7, 14)
- Period 2: Change From Baseline in pH of Urine(Baseline and at Days 3, 7, 9)
- Period 1: Absolute Values of pH of Urine(Baseline and at Days 7, 14)
- Period 2: Absolute Values of pH of Urine(Baseline and at Days 3, 7, 9)
- Period 1: Change From Baseline in Urine Urobilinogen(Baseline and at Days 7, 14)
- Period 2: Change From Baseline in Urine Urobilinogen(Baseline and at Days 3, 7, 9)
- Period 1: Absolute Values of Urine Urobilinogen(Baseline and at Days 7, 14)
- Period 2: Absolute Values of Urine Urobilinogen(Baseline and at Days 3, 7, 9)
- Period 1: Change From Baseline in Heart Rate(Baseline and at Day 1, 2 and 4 hours post-dose)
- Period 2: Change From Baseline in Heart Rate(Baseline and at Day 1, 2 and 4 hours post-dose; Day 4, Pre-dose, 2 and 4 hours post-dose; Day 7, Pre-dose, 2 and 4 hours post-dose; Day 9 post-dose)
- Period 1: Absolute Values of Heart Rate(Baseline and at Day 1, 2 and 4 hours post-dose)
- Period 2: Absolute Values of Heart Rate(Baseline and at Day 1, 2 and 4 hours post-dose; Day 4, Pre-dose, 2 and 4 hours post-dose; Day 7, Pre-dose, 2 and 4 hours post-dose; Day 9 post-dose)
- Period 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF) Interval, and Bazett QT Correction Formula (QTcB) Interval(Baseline and at Day 1, 2 and 4 hours post-dose)
- Period 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval, and QTcB Interval(Baseline and at Day 1, 2 and 4 hours post-dose; Day 4, Pre-dose, 2 and 4 hours post-dose; Day 7, Pre-dose, 2 and 4 hours post-dose; Day 9 post-dose)
- Period 1: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval, and QTcB Interval(Baseline and at Day 1, 2 and 4 hours post-dose)
- Period 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval, and QTcB Interval(Baseline and at Day 1, 2 and 4 hours post-dose; Day 4, Pre-dose, 2 and 4 hours post-dose; Day 7, Pre-dose, 2 and 4 hours post-dose; Day 9 post-dose)
- Period 1: Change From Baseline in Temperature(Baseline and at Days 2, 3, 4, 5 and 7)
- Period 2: Change From Baseline in Temperature(Baseline and at Days 4, 7, 9, and 10)
- Period 1: Absolute Values of Temperature(Baseline and at Days 2, 3, 4, 5 and 7)
- Period 2: Absolute Values of Temperature(Baseline and at Days 4, 7, 9, and 10)
- Period 1: Change From Baseline in Pulse Rate(Baseline and at Days 2, 3, 4, 5 and 7)
- Period 2: Change From Baseline in Pulse Rate(Baseline and at Days 4, 7, 9, and 10)
- Period 1: Absolute Values of Pulse Rate(Baseline and at Days 2, 3, 4, 5 and 7)
- Period 2: Absolute Values of Pulse Rate(Baseline and at Days 4, 7, 9, and 10)
- Period 1: Change From Baseline in Respiratory Rate(Baseline and at Days 2, 3, 4, 5 and 7)
- Period 2: Change From Baseline in Respiratory Rate(Baseline and at Days 4, 7, 9, and 10)
- Period 1: Absolute Values of Respiratory Rate(Baseline and at Days 2, 3, 4, 5 and 7)
- Period 2: Absolute Values of Respiratory Rate(Baseline and at Days 4, 7, 9, and 10)
- Period 1: Change From Baseline in Blood Pressure(Baseline and at Days 2, 3, 4, 5 and 7)
- Period 2: Change From Baseline in Blood Pressure(Baseline and at Days 4, 7, 9, and 10)
- Period 1: Absolute Values of Blood Pressure(Baseline and at Days 2, 3, 4, 5 and 7)
- Period 2: Absolute Values of Blood Pressure(Baseline and at Days 4, 7, 9, and 10)
- Period 2: AUC (0-tau) of GSK3640254(Pre-dose, 1 and 2hours, 2 hours 30 minutes, 3 and 3 hour 30 minutes, 4 and 4 hour 30 minutes, 5, 6, 8, 12 and 24 hours in Period 2 Day 7)
- Period 2: Cmax of GSK3640254(Pre-dose, 1 and 2hours, 2 hours 30 minutes, 3 and 3 hour 30 minutes, 4 and 4 hour 30 minutes, 5, 6, 8, 12 and 24 hours in Period 2 Day 7)
- Period 2: Ctau of GSK3640254(Pre-dose, 1 and 2 hours, 2 hours 30 minutes, 3 and 3 hour 30 minutes, 4 and 4 hour 30 minutes, 5, 6, 8, 12 and 24 hours in Period 2 Day 7)
- Period 2: Time of Maximum Observed Concentration (Tmax) of GSK3640254(Pre-dose, 1 and 2hours, 2 hours 30 minutes, 3 and 3 hour 30 minutes, 4 and 4 hour 30 minutes, 5, 6, 8, 12 and 24 hours in Period 2 Day 7)
- Period 1: Tmax of TAF(Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14)
- Period 2: Tmax of TAF(Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7)
- Period 1: Tmax of FTC(Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14)
- Period 2: Tmax of FTC(Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7)
- Period 1: Tmax of TFV(Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14)
- Period 2: Tmax of TFV(Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7)